Arbutus Biopharma Corp (NASDAQ: ABUS) is a Healthcare company (Biotechnology) with a market capitalization of $621M. The Maz Rating grades it against the other companies in its sector.
Arbutus Biopharma Corp's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.05, Arbutus Biopharma Corp trades at 3.6x trailing earnings, 3.4x sales and 9.4x book value, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $182M of revenue and $174M of net income. It runs an operating margin of 79.9% and a net margin of 121.2%. It shows return on equity of 129.1%, return on invested capital of 147.8% and a free cash flow yield of 35.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 1.40. Over the past 52 weeks the share price ranged from $3.04 to $5.45, with a beta of 0.62.
Arbutus Biopharma Corp does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.